Narrow search
Showing 1 - 10 of 1,436
Cover Image
The Economic Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: Can Drugs Ease the Burden?
Murman, Daniel L.; Colenda, Christopher C. - In: PharmacoEconomics 23 (2005) 3, pp. 227-242
The majority of patients with Alzheimer's disease (AD) will have clinically significant neuropsychiatric symptoms during the course of their disease. There is growing evidence that neuropsychiatric symptoms increase direct costs of care in patients with AD, especially the costs associated with...
Persistent link: https://www.econbiz.de/10005449320
Cover Image
Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France
Nuijten, Mark; Hadjadjeba, Lionel; Evans, Christopher; … - In: PharmacoEconomics 14 (1998) 4, pp. 433-445
constructed to model the effectiveness, as measured by time without depression, and the costs of both treatments. The model … favoured fluvoxamine as it was associated with a longer period of time without depression when compared with TCAs (79% of the …
Persistent link: https://www.econbiz.de/10005404792
Cover Image
Reducing the Societal Burden of Depression: A Review of Economic Costs, Quality of Care and Effects of Treatment
Donohue, Julie M.; Pincus, Harold Alan - In: PharmacoEconomics 25 (2007) 1, pp. 7-24
Depression is a highly prevalent condition that results in substantial functional impairment. Advocates have attempted … in recent years to make the `business case' for investing in quality improvement efforts in depression care, particularly … in primary care settings. The business case suggests that the costs of depression treatment may be offset by gains in …
Persistent link: https://www.econbiz.de/10004990342
Cover Image
Cost of Illness of Cystic Fibrosis in Germany: Results from a Large Cystic Fibrosis Centre
Heimeshoff, Mareike; Hollmeyer, Helge; Schreyogg, Jonas … - In: PharmacoEconomics 30 (2012) 9, pp. 763-777
Background:Background: Cystic fibrosis (CF) is the most common life-shortening genetic disorder among Whites worldwide. Because many of these patients experience chronic endobronchial colonization and have to take antibiotics and be treated as inpatients, societal costs of CF may be high. As the...
Persistent link: https://www.econbiz.de/10011005071
Cover Image
Medical Resource Utilization and Cost of HIV-Related Care in the Highly Active Antiretroviral Therapy Era at a University Clinic in Sweden
Ghatnekar, Ola; Hjortsberg, Catharina; Gisslén, Magnus … - In: PharmacoEconomics 28 (2010) S1, pp. 49-57
Introduction: Little is known regarding healthcare costs for HIV/AIDS patients in the era of highly active antiretroviral therapy (HAART) and subgroups of patients according to the severity and progression of HIV infection in Sweden. The objective of this study is therefore to describe the...
Persistent link: https://www.econbiz.de/10011005075
Cover Image
Management and Costs of Treating Lung Cancer Patients in a University Hospital
Dedes, Konstantin J.; Szucs, Thomas D.; Bodis, Stephan; … - In: PharmacoEconomics 22 (2004) 7, pp. 435-444
Background: New diagnostic tools and emerging medications have significantly changed the existing medical treatment options for lung cancer over the last 5 years. However, the increase in healthcare costs in all developed societies has put the more economical treatments on centre stage....
Persistent link: https://www.econbiz.de/10005243083
Cover Image
Cost of Stress Urinary Incontinence: A Claims Data Analysis
Birnbaum, Howard G.; Leong, Stephanie A.; Oster, Emily F.; … - In: PharmacoEconomics 22 (2004) 2, pp. 95-105
Objectives: The primary objectives of this research were to: (i) identify and present methodologies for estimating three types of Study Design and Methods: In this paper, we discuss aspects of cost-of-illness methodologies in the context of SUI. We first distinguish between Results: The three...
Persistent link: https://www.econbiz.de/10005243096
Cover Image
Assessing the Annual Economic Burden of Preventing and Treating Anogenital Human Papillomavirus-Related Disease in the US: Analytic Framework and Review of the Literature
Insinga, Ralph P.; Dasbach, Erik J.; Elbasha, Elamin H. - In: PharmacoEconomics 23 (2005) 11, pp. 1107-1122
The anogenital human papillomavirus (HPV) is estimated to be the most commonly occurring sexually transmitted infection in the US. Comprehensive estimates of the annual economic burden associated with the prevention and treatment of anogenital HPV-related disease in the US population are...
Persistent link: https://www.econbiz.de/10005243142
Cover Image
Heartburn in Patients with Gastro-Oesophageal Reflux Disease in Germany and Sweden: A Study on Patients
Jones, Roger; Horbach, Silke; Sander, Peter; … - In: PharmacoEconomics 21 (2003) 15, pp. 1091-1102
Background: Gastro-oesophageal reflux disease (GORD) is widespread in the general population and presents in most cases with heartburn as the main symptom. The severity of symptoms is not necessarily related to erosive damage to the oesophagus due to acid reflux, but the frequency and severity...
Persistent link: https://www.econbiz.de/10005243175
Cover Image
Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006
Birnbaum, Howard G.; Pike, Crystal; Banerjee, Ritesh; … - In: PharmacoEconomics 30 (2012) 4, pp. 323-336
Background:Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease that often results in joint pain, inflammation and bone erosions. Perhaps the most notable change in RA treatment during the last decade is the advent of biologics, and, in particular, anti-tumour necrosis factor...
Persistent link: https://www.econbiz.de/10009653281